TLR3 and cancer: For instance, by activating Toll-like receptor 3 (TLR3), anthracyclines stimulate production of type I IFNs by cancer cells, and tumors lacking TLR3 or IFN-α receptor fail to respond to anthracycline chemotherapy32.